Epigenetic modulator LSD1, a theragnostic target for potentially malignant oral disorders and malignant lesions

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer. J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 2. Bais MV. Targeting oral cancer epigenome via LSD1. Aging (Albany NY). 9(12), 2455–2456 (2017).
  MedlineGoogle Scholar
• 3. Dorna D, Paluszczak J. The emerging significance of histone lysine demethylases as prognostic markers and therapeutic targets in head and neck cancers. Cells 11(6), 1023 (2022). •• Describes the role of lysine demethylases in head and neck cancers.
  Medline CASGoogle Scholar
• 4. Kim D, Kim KI, Baek SH. Roles of lysine-specific demethylase 1 (LSD1) in homeostasis and diseases. J. Biomed. Sci. 28(1), 41 (2021).
  Medline CASGoogle Scholar
• 5. Bottner J, Ribbat-Idel J, Klapper L et al. Elevated LSD1 and SNAIL expression indicate poor prognosis in hypopharynx carcinoma. Int. J. Mol. Sci. 23(9), 5075 (2022). •• Describes the prognostic ability of LSD1 in hypopharynx carcinoma.
  Medline CASGoogle Scholar
• 6. Alsaqer SF, Tashkandi MM, Kartha VK et al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 8(43), 73372–73386 (2017). •• Describes the therapeutic strategy exerted by attenuation of LSD1.
  MedlineGoogle Scholar
• 7. Sheng W, LaFleur MW, Nguyen TH et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell. 174(3), 549–563.e19 (2018).
  Medline CASGoogle Scholar
• 8. Yuan C, Li Z, Qi B et al. High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer. J. Oral. Pathol. Med. 44(2), 159–65 (2015). •• Describes the prognostic ability of LSD1 in tongue cancer.
  Medline CASGoogle Scholar
• 9. Wang Y, Zhu Y, Wang Q et al. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer. Cancer. Lett. 374(1), 12–21 (2016). • Describes LSD1 as an oncogene and therapeutic lead.
  Medline CASGoogle Scholar
• 10. Yang CY, Lin CK, Tsao CH et al. Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models. Oncotarget. 8(20), 33756–33769 (2017).
  MedlineGoogle Scholar
• 11. Zhang W, Cheng J, Diao P et al. Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1. Br. J. Cancer. 122(4), 528–538 (2020). • Describes the potential of LSD1 as a therapeutic target.
  Medline CASGoogle Scholar
• 12. Han Y, Xu S, Ye W et al. Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade. Cell. Death. Dis. 12(11), 993 (2021). • Describes the role of LSD1 in conferring stemness to the cancer cells.
  Medline CASGoogle Scholar
• 13. Wangzhou K, Fu W, Li M et al. microRNA-17 is a tumor suppressor in oral squamous cell carcinoma and is repressed by LSD1. Oral. Dis. doi: 10.1111/odi.13944 (2021) (Online ahead of print). • Describes microRNA targets of LSD1.
  Google Scholar
• 14. Alhousami T, Diny M, Ali F et al. Inhibition of LSD1 attenuates oral cancer development and promotes therapeutic efficacy of immune checkpoint blockade and YAP/TAZ inhibition. Mol. Cancer. Res. 20(5), 712–721 (2022). •• Describes the therapeutic efficacy of LSD1 in attenuating oral cancer.
  Medline CASGoogle Scholar
• 15. Fang Y, Liao G, Yu B. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J. Hematol. Oncol. 12(1), 129 (2019).
  MedlineGoogle Scholar